Orlistat – 250 mg

Brand:
Cayman
CAS:
96829-58-2
Storage:
-20
UN-No:
Non-Hazardous - /

Orlistat inhibits gastric, pancreatic, and carboxyl ester lipases, preventing the hydrolysis of triglycerides to free fatty acids and monoglycerides, and as such is widely used to treat obesity.{18001} With a 120 mg dose before each meal in healthy subjects, orlistat is reported to accelerate gastric emptying and attenuates the secretion of glucose-dependent insulinotropic peptide without affecting plasma responses of cholecystokinin, glucagon-like peptide-1, pancreatic polypeptide, or insulin. {18002} It also targets additional serine hydrolases in the nervous system, such as diacylglycerol lipase (DAGL), which is responsible for the conversion of DAG to 2-AG. Orlistat potently inhibits human recombinant DAGLα with an IC50 value of 60 nM and at 1 µM inhibits the formation of 2-AG in intact cells in vitro.{14179}  

 

Available on backorder

SKU: 10005426 - 250 mg Category:

Description

An anti-obesity drug that inhibits gastric, pancreatic, and carboxyl ester lipases, preventing hydrolysis of triglycerides to free fatty acids and monoglycerides; potently inhibits human recombinant DAGLα (IC50 = 60 nM) and at 1 µM inhibits the formation of 2-AG in intact cells


Formal name: N-formyl-L-leucine-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester

Synonyms:  Tetrahydrolipstatin

Molecular weight: 495.7

CAS: 96829-58-2

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity